CYP2C9 gene polymorphism in the pharmacological treatment of long QT patients.
Sławomir
S
Smolik
Ewa
E
Moric-Janiszewska
Ludmiła
L
Węglarz
D015331:Cohort Studies; D065729:Cytochrome P-450 CYP2C9 / Q000235:genetics*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005787:Gene Frequency; D006801:Humans; D008133:Long QT Syndrome / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D019808:Losartan / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D011110:Polymorphism, Genetic; D014859:Warfarin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use
D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D019808:Losartan